Drug Trial Radar · NCT00232180
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
Last checked: Nov 20, 2026Latest source record: Dec 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,743
Actual
Start
Mar 2006
Primary completion
May 2010
Study completion Jan 2012
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 4, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack. However, it is not known how patients with established mild-to-moderate heart failure (NYHA Class II), who have the additional risk of sudden death, will respond if treated with eplerenone. In this trial, eplerenone plus standard heart failure medicines is being compared to placebo plus standard heart failure medicines in terms of an additional ability to prolong life and prevent re-hospitalizations for worsening heart failure in these patients. The Data Safety Monitoring Committee (DSMC) observed during its conduct of the protocol-specified second interim analysis on the 6th of May, 2010 that the efficacy of eplerenone had met the pre-specified stopping rules in the protocol. As a result of the discussion between the DSMC and the Executive Steering Committee (ESC), the ESC recommended that EMPHASIS-HF should be terminated, Based on the convincing efficacy and the consideration that it would be unethical not to offer this treatment to patients, the ESC recommended that all the patients in the trial should be transferred to open-label eplerenone. The Open Label Extension eplerenone arm will last for 12 months. Eplerenone is not currently approved for the indication studied in this patient population. On May 26, 2010, further enrollment into EMPHASIS-HF was stopped. The amendment is considered to be the most appropriate way to ensure that all the subjects who participated in the double-blind phase of the EMPHASIS-HF trial can be offered treatment with eplerenone
Conditions
- Heart Failure
Interventions
EplerenoneDrug
Eplerenone administered on top of background standard heart failure therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off DateTime frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)
- Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated)Time frame: Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)
Locations
307 sites in 29 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Loma Linda, California
Pfizer Investigational Site
Merced, California
Pfizer Investigational Site
Stockton, California
Pfizer Investigational Site
Colorado Springs, Colorado
Pfizer Investigational Site
Bridgeport, Connecticut
Pfizer Investigational Site
Hartford, Connecticut
Pfizer Investigational Site
Washington D.C., District of Columbia
Pfizer Investigational Site
Daytona Beach, Florida
Pfizer Investigational Site
Gainesville, Florida
Pfizer Investigational Site
Jupiter, Florida
Pfizer Investigational Site
Melbourne, Florida
Pfizer Investigational Site
Rockford, Illinois
Pfizer Investigational Site
Indianapolis, Indiana
Pfizer Investigational Site
Indianapolis, Indiana
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
Baton Rouge, Louisiana
Pfizer Investigational Site
Bangor, Maine
Pfizer Investigational Site
Annapolis, Maryland
Pfizer Investigational Site
Columbia, Maryland
Pfizer Investigational Site
Boston, Massachusetts
Pfizer Investigational Site
Minneapolis, Minnesota
Pfizer Investigational Site
MN, Minnesota
Pfizer Investigational Site
Tupelo, Mississippi
Pfizer Investigational Site
Tupelo, Mississippi
Pfizer Investigational Site
Omaha, Nebraska
Pfizer Investigational Site
Omaha, Nebraska
Pfizer Investigational Site
Omaha, Nebraska
Pfizer Investigational Site
Manchester, New Hampshire
Pfizer Investigational Site
Albany, New York
Pfizer Investigational Site
Rochester, New York
Pfizer Investigational Site
Rochester, New York
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Oklahoma City, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma
Pfizer Investigational Site
Beaver, Pennsylvania
Pfizer Investigational Site
Doylestown, Pennsylvania
Showing 40 of 307 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.